ESOC 2025 | The potential of blood-based biomarkers to differentiate ischemic and hemorrhagic stroke
Maria Alonso De Leciñana, MD, PhD, La Paz University Hospital, Madrid, Spain, comments on the potential of blood-based biomarkers in hemorrhagic stroke. She states that while promising, they are not yet ready for clinical implementation, but ongoing research and clinical trials are ongoing to verify their efficacy. Dr Leciñana highlights the potential of combining biomarkers to differentiate hemorrhagic from ischemic stroke, allowing for more accurate pre-hospital decision-making. This interview took place at the 11th European Stroke Organisation Conference (ESOC) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
I must first say that blood biomarkers in hemorrhagic stroke look promising, but at the moment I think we are not there yet. We have some really interesting data from the current studies, but there are some limitations to implement these biomarkers in clinical practice. I’m sure that is the future, but we are not there yet. We should keep on working on them and keep on doing more research and clinical trials to really verify what the reality of these biomarkers is. But at the moment, we have some tools which can help us for early diagnosis of hemorrhagic stroke and mainly to differentiate hemorrhagic stroke from ischemic stroke. The most promising biomarkers in this regard are GFAP, glial fibrillary acidic protein, which is really increased in hemorrhagic stroke in comparison with ischemic stroke. But especially if it is combined with other biomarkers that are really high in ischemic stroke and not in hemorrhagic stroke, which are [inaudible] and BNP. If we combine high levels of these biomarkers with negative GFAP, then we can, with high specificity, say that we are discarding hemorrhagic stroke. So this may help in pre-clinical, pre-hospital decisions to transfer patients to certain treatments, for specific treatments, I mean.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
